Judy Stewart, GSK’s head of vaccines in the US (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: GSK vac­cine leader Judy Stew­art nav­i­gates vac­ci­na­tion slumps, al­ways-on mar­ket­ing and in­no­vat­ing da­ta tools

It’s been a tough cou­ple of years for tra­di­tion­al vac­cine mak­ers. While the Covid-19 pan­dem­ic spurred a flur­ry of in­no­va­tion and turned a white-hot spot­light on the footrace for Covid vac­cine ap­provals, rou­tine vac­ci­na­tion rates plum­met­ed.

Ear­ly re­stric­tions, on­go­ing health pre­cau­tions and sup­ply chain is­sues caused mil­lions of peo­ple to skip rec­om­mend­ed vac­cines by the end of 2021. The World Health Or­ga­ni­za­tion re­cent­ly re­port­ed that 2021 suf­fered “the largest sus­tained de­cline in child­hood vac­ci­na­tions” in 30 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.